Nature Medicine：阿尔茨海默病新药2期临床试验失败

Core Viewpoint - TREM2 is a significant risk gene for Alzheimer's disease, and its deficiency or mutation can significantly increase the risk of developing the disease [2] Group 1: Clinical Trial Overview - Alector's humanized TREM2 agonistic monoclonal antibody AL002 is undergoing clinical trials for Alzheimer's disease [2] - A phase 2 randomized controlled trial involving 381 early Alzheimer's disease patients was conducted, with participants receiving AL002 or a placebo [4] - The trial had a 1:1:1:1 randomization ratio for doses of AL002 (15mg/kg, 40mg/kg, or 60mg/kg) or placebo, administered intravenously every 4 weeks for 48-96 weeks [4] Group 2: Trial Results - AL002 showed sustained target engagement and pharmacodynamic response in the central nervous system, indicated by decreased soluble TREM2 levels and increased osteopontin levels in cerebrospinal fluid [4] - The trial did not meet its primary endpoint, with the least squares mean differences at week 96 for the 15mg/kg, 40mg/kg, and 60mg/kg groups compared to the placebo being -0.31, 0.13, and -0.17, respectively [4] - The most common adverse events were MRI findings resembling amyloid-related imaging abnormalities (ARIA) [4] Group 3: Implications - The negative results of this first TREM2 agonistic antibody trial for early Alzheimer's disease provide important references for TREM2-targeted therapies and ARIA research [4]